General Information of Drug Therapeutic Target (DTT) (ID: TTRFOXJ)

DTT Name Protein kinase C gamma (PRKCG)
Synonyms PRKCG; PKCG; PKC-gamma
Gene Name PRKCG
DTT Type
Successful target
[1]
BioChemical Class
Kinase
UniProt ID
KPCG_HUMAN
TTD ID
T47107
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.11.13
Sequence
MAGLGPGVGDSEGGPRPLFCRKGALRQKVVHEVKSHKFTARFFKQPTFCSHCTDFIWGIG
KQGLQCQVCSFVVHRRCHEFVTFECPGAGKGPQTDDPRNKHKFRLHSYSSPTFCDHCGSL
LYGLVHQGMKCSCCEMNVHRRCVRSVPSLCGVDHTERRGRLQLEIRAPTADEIHVTVGEA
RNLIPMDPNGLSDPYVKLKLIPDPRNLTKQKTRTVKATLNPVWNETFVFNLKPGDVERRL
SVEVWDWDRTSRNDFMGAMSFGVSELLKAPVDGWYKLLNQEEGEYYNVPVADADNCSLLQ
KFEACNYPLELYERVRMGPSSSPIPSPSPSPTDPKRCFFGASPGRLHISDFSFLMVLGKG
SFGKVMLAERRGSDELYAIKILKKDVIVQDDDVDCTLVEKRVLALGGRGPGGRPHFLTQL
HSTFQTPDRLYFVMEYVTGGDLMYHIQQLGKFKEPHAAFYAAEIAIGLFFLHNQGIIYRD
LKLDNVMLDAEGHIKITDFGMCKENVFPGTTTRTFCGTPDYIAPEIIAYQPYGKSVDWWS
FGVLLYEMLAGQPPFDGEDEEELFQAIMEQTVTYPKSLSREAVAICKGFLTKHPGKRLGS
GPDGEPTIRAHGFFRWIDWERLERLEIPPPFRPRPCGRSGENFDKFFTRAAPALTPPDRL
VLASIDQADFQGFTYVNPDFVHPDARSPTSPVPVPVM
Function
Calcium-activated, phospholipid-and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and may be critical for the development and/or maintenance ofmorphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation anddegradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress. Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component ARNTL/BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resultingin phase resetting of the cerebral cortex clock.
KEGG Pathway
MAPK signaling pathway (hsa04010 )
ErbB signaling pathway (hsa04012 )
Ras signaling pathway (hsa04014 )
Rap1 signaling pathway (hsa04015 )
Calcium signaling pathway (hsa04020 )
HIF-1 signaling pathway (hsa04066 )
Phosphatidylinositol signaling system (hsa04070 )
Sphingolipid signaling pathway (hsa04071 )
mTOR signaling pathway (hsa04150 )
Vascular smooth muscle contraction (hsa04270 )
Wnt signaling pathway (hsa04310 )
VEGF signaling pathway (hsa04370 )
Focal adhesion (hsa04510 )
Tight junction (hsa04530 )
Gap junction (hsa04540 )
Natural killer cell mediated cytotoxicity (hsa04650 )
Fc gamma R-mediated phagocytosis (hsa04666 )
Leukocyte transendothelial migration (hsa04670 )
Circadian entrainment (hsa04713 )
Long-term potentiation (hsa04720 )
Retrograde endocannabinoid signaling (hsa04723 )
Glutamatergic synapse (hsa04724 )
Cholinergic synapse (hsa04725 )
Serotonergic synapse (hsa04726 )
GABAergic synapse (hsa04727 )
Dopaminergic synapse (hsa04728 )
Long-term depression (hsa04730 )
Inflammatory mediator regulation of TRP channels (hsa04750 )
Insulin secretion (hsa04911 )
Melanogenesis (hsa04916 )
Thyroid hormone synthesis (hsa04918 )
Thyroid hormone signaling pathway (hsa04919 )
Oxytocin signaling pathway (hsa04921 )
Aldosterone-regulated sodium reabsorption (hsa04960 )
Endocrine and other factor-regulated calcium reabsorption (hsa04961 )
Salivary secretion (hsa04970 )
Gastric acid secretion (hsa04971 )
Pancreatic secretion (hsa04972 )
Amphetamine addiction (hsa05031 )
Morphine addiction (hsa05032 )
Vibrio cholerae infection (hsa05110 )
African trypanosomiasis (hsa05143 )
Amoebiasis (hsa05146 )
Hepatitis B (hsa05161 )
Pathways in cancer (hsa05200 )
Proteoglycans in cancer (hsa05205 )
MicroRNAs in cancer (hsa05206 )
Glioma (hsa05214 )
Non-small cell lung cancer (hsa05223 )
Choline metabolism in cancer (hsa05231 )
Reactome Pathway
Disinhibition of SNARE formation (R-HSA-114516 )
Trafficking of GluR2-containing AMPA receptors (R-HSA-416993 )
G alpha (z) signalling events (R-HSA-418597 )
WNT5A-dependent internalization of FZD4 (R-HSA-5099900 )
Response to elevated platelet cytosolic Ca2+ (R-HSA-76005 )
Calmodulin induced events (R-HSA-111933 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [1]
------------------------------------------------------------------------------------
3 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BALANOL DMDLN9E N. A. N. A. Terminated [2]
LY-317644 DMM20PI N. A. N. A. Terminated [3]
RO-320432 DMFZ1YW N. A. N. A. Terminated [4]
------------------------------------------------------------------------------------
25 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(-)-Cercosporamide DMJ249P Discovery agent N.A. Investigative [5]
2,3,3-Triphenyl-acrylonitrile DM7H34U Discovery agent N.A. Investigative [6]
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A Discovery agent N.A. Investigative [6]
3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG Discovery agent N.A. Investigative [6]
3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 Discovery agent N.A. Investigative [6]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [7]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [7]
3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 Discovery agent N.A. Investigative [6]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [7]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [7]
4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC Discovery agent N.A. Investigative [6]
4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 Discovery agent N.A. Investigative [6]
4-cyclopentyliden(4-hydroxyphenyl)methylphenol DM7LN53 Discovery agent N.A. Investigative [6]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 Discovery agent N.A. Investigative [6]
8-Octyl-benzolactam-V9 DM4Z15M Discovery agent N.A. Investigative [8]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [9]
Go 6983 DMKVTZN Discovery agent N.A. Investigative [10]
LY-326449 DMN53M4 Discovery agent N.A. Investigative [11]
Monoctanoin component C DM31YGM Discovery agent N.A. Investigative [12]
PROSTRATIN DM1HMJ5 Human immunodeficiency virus infection 1C62 Investigative [13]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [14]
Ro-32-0557 DMPVKEA Discovery agent N.A. Investigative [4]
[2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F Discovery agent N.A. Investigative [15]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI Discovery agent N.A. Investigative [15]
[2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ Discovery agent N.A. Investigative [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2C82 Bone marrow 9.42E-04 0.06 0.3
Colon cancer 2C82 Colon tissue 2.49E-01 -0.02 -0.1
Breast cancer 2C82 Breast tissue 5.25E-10 -0.07 -0.35
------------------------------------------------------------------------------------

References

1 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
2 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
3 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
4 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
5 (-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6.
6 Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
7 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
8 Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
9 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
10 Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
11 (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
12 Synthesis and characterization of the second cysteine-rich region of mouse skin PKCGh, Bioorg. Med. Chem. Lett. 6(4):353-356 (1996).
13 A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
14 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
15 Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.